Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
AbstractBruton’s tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor (BCR) pathway. BTK activation has been implicated in the pathogenesis of certain B-cell malignancies. Targeting this pathway has emerged as a novel target in B-cell malignancies, of which ibrutinib is the first-in-class agent. A few other BTK inhibitors (BTKi) are also under development (e.g., acalabrutinib). While the predominant action of BTKi is the blockade of B-cell receptor pathway within malignant B-cells, increasing the knowledge of off-target effects as well as a potential role for B-cells in proliferation of solid malignancies is expanding the indication of BTKi into non-hematological malignancies. In addition to the expansion of the role of BTKi monotherapy, combination therapy strategies utilizing ibrutinib with established regimens and combination with modern immunotherapy compounds are being explored. View Full-Text
Share & Cite This Article
Campbell, R.; Chong, G.; Hawkes, E.A. Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. J. Clin. Med. 2018, 7, 62.
Campbell R, Chong G, Hawkes EA. Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. Journal of Clinical Medicine. 2018; 7(4):62.Chicago/Turabian Style
Campbell, Robert; Chong, Geoffrey; Hawkes, Eliza A. 2018. "Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies." J. Clin. Med. 7, no. 4: 62.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.